ICER Outlines Planned Review for Beta Thalassemia Treatments
January 7, 2020
The Institute for Clinical and Economic Review (ICER) on Monday released a new document outlining a planned review of LentiGlobin and luspatercept-aamt for the treatment of beta thalassemia.
According to a press release, the Food and Drug Administration is set to make a decision on LentiGlobin late this year.
ICER is accepting public input on the document until 5 p.m. EST Jan. 27.
To read the draft scoping document, click here.
